The US government (USG) investment in global health R&D has delivered $410 million to North Carolina research institutions and 5,900 new jobs for North Carolina.

North Carolina’s top global health R&D institutions by USG funding:

- **Duke University**: $250.1 million
- **FHI 360**: $91.0 million
- **University of North Carolina**: $46.4 million
- **University of North Carolina Chapel Hill**: $13.4 million
- **RTI International**: $5.0 million
- **North Carolina State University Raleigh**: $2.9 million
- **Wake Forest University**: $553 thousand

North Carolina’s top areas of global health R&D by USG funding:

- HIV/AIDS: 84%
- Malaria: 4.6%
- Tuberculosis: 4.4%
- NTDs: 2.8%
- Other: 4.3%

Global health R&D at work in the Tar Heel State:

RTI International, in partnership with TB Alliance, is supporting development of new drugs for tuberculosis. One new drug therapy, PaMZ, promises to dramatically shorten and simplify treatment for multidrug-resistant tuberculosis (MDR-TB). Today people with MDR-TB face up to two years of treatment with only a 50 percent success rate. This game-changing therapy now in late-stage development is expected to decrease treatment to 6 months and reduce costs by 90 percent.

USG investment in global health R&D between 2007 and 2015 generated an estimated:

- 200,000 new US jobs
- $33 billion in US economic growth
- 89¢ of every dollar the USG invests in global health R&D stays within the United States, supporting the domestic economy.